Leading pharmaceutical company Hetero on Monday announced that it has received the World Health Organization Prequalification of Medicines Programme (Who Pq) approval for its generic version of Covid-19 oral antiviral treatment candidate Nirmatrelvir.
This is the first pre-qualification for a generic version of Pfizer’s Covid-19 oral antiviral drug ‘Paxlovid’, which the Who called, the best therapeutic choice for high-risk patients to date.
Who made a strong recommendation for Nirmatrelvir and Ritonavir for mild and moderate Covid-19 patients at highest risk of hospital admission, such as unvaccinated, aged, or immunosuppressed patients, the company said
The combi pack, launched by Hetero as Nirmacom,will contain nirmatrelvir 150 mg (2 tablets) and ritonavir 100mg (1 tablet). It is available by prescription only and should be initiated as soon as possible after diagnosis of Covid-19 and within five days of symptom onset.
Nirmacom will be manufactured at Hetero’s facilities in India.
“Who Prequalification for Nirmacom...
This is the first pre-qualification for a generic version of Pfizer’s Covid-19 oral antiviral drug ‘Paxlovid’, which the Who called, the best therapeutic choice for high-risk patients to date.
Who made a strong recommendation for Nirmatrelvir and Ritonavir for mild and moderate Covid-19 patients at highest risk of hospital admission, such as unvaccinated, aged, or immunosuppressed patients, the company said
The combi pack, launched by Hetero as Nirmacom,will contain nirmatrelvir 150 mg (2 tablets) and ritonavir 100mg (1 tablet). It is available by prescription only and should be initiated as soon as possible after diagnosis of Covid-19 and within five days of symptom onset.
Nirmacom will be manufactured at Hetero’s facilities in India.
“Who Prequalification for Nirmacom...
- 12/26/2022
- by Glamsham Bureau
- GlamSham
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.